Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment

Japanese Journal of Clinical Oncology

Volumn 39, Issue 11, 2009, Pages 699-706

  Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a   Fujiwara, Yasuhiro ^b   Iwata, Hiroji ^c   Sasaki, Yasutsuna ^d   Saji, Shigehira ^d,e   Aogi, Kenjiro ^f   Nambu, Yoshihiro ^g   Suri, Ajit ^g   Saeki, Toshiaki ^d   Takashima, Shigemitsu ^f  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Anthracycline and taxane pre treated; Chemotherapy; Gemcitabine; Metastatic breast cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE HEART FAILURE; ADULT; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; BRAIN EDEMA; BRAIN METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER GROWTH; CANCER PATIENT; CATARACT; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEMUR FRACTURE; HUMAN; HYPERTENSION; HYPOXIA; INFECTION; JAPAN; LEUKOPENIA; LIMB PAIN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NECROSIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RAYNAUD PHENOMENON; RESPIRATORY FAILURE; SALVAGE THERAPY; SIDE EFFECT; SKIN METASTASIS; SURVIVAL TIME; WHEEZING;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TAXOIDS; TREATMENT OUTCOME;

EID: 70449333314     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp103     Document Type: Article

References (30)

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205.
2. Elder EE, Kennedy CW, Gluch L, Carmalt HL, Janu NC, Joseph MG, et al. Patterns of breast cancer relapse. In: DeVita VT, Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 1700-1.
3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
5. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20:3106-13.
6. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997;33(Suppl 1):S18-22.
7. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
8. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006;57:647-53.
9. Oliveras-Ferraros C, Vazquez-Martin A, Colomer R, De Llorens R, Brunet J, Menendez JA. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling. Int J Oncol 2008;32:113-20.
10. Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA, Jr. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin Breast Cancer 2002; 3(Suppl 1):12-6.
11. Bunn PA, Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001;7:3239-50.
12. Possinger K, Kaufmann M, Coleman R, Stuart NS, Helsing M, Ohnmacht U, et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 1999;10:155-62.
13. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 2002;62:2-8.
14. Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303-7.
15. Brodowicz T, Kostler WJ, Möslinger R, Tomek S, Vaclavik I, Herscovici V, et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000;9:338-42.
16. Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;90:215-21.
17. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7.
18. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
19. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
20. von Minckwitz G, for The Breast Commission of the German Gynaecological Oncology Working Group (AGO). Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission. Eur J Cancer 2006;42:2897-908.
21. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
22. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-68.
23. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-42.
24. Reichadt P, von Minckwitz G, Thuss-Patience PC, Janat W, Kölbl H, Jänicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14: 1227-33.
25. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 1994;12:2094-101.
26. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-400.
27. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567-74.
28. Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 2005;35:310-5.
29. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane or both. J Clin Oncol 2004;22:2849-55.
30. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753-60.